Across TCGA pan-cancer cohorts, IGKV5-2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IGKV5-2 data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher IGKV5-2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGKV5-2 expression acts as an unfavorable survival marker.

ACC, GBM, and PRAD are the cancer types where IGKV5-2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
GBM	DFS	Median	All	0.031	0.257	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	OS	Median	All	0.081	0.818	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: IGKV5-2 tumor-vs-normal RNA expression · all IGKV5-2 data types